{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=37", "query": { "condition": "Melanoma Neoplasms", "page": 37 }, "page_size": 10 }, "pagination": { "page": 37, "page_size": 10, "total_count": 2205, "total_pages": 221, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=38&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=36&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T12:48:51.795Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02646748", "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer (CRC)", "Endometrial Cancer", "Melanoma", "Head and Neck Cancer", "Lung Cancer", "MMR-deficient Tumors", "Breast Cancer", "Pancreatic Cancer", "Renal Cell Carcinoma (RCC)", "Solid Tumors", "UC (Urothelial Cancer)" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "itacitinib", "type": "DRUG" }, { "name": "INCB050465", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2016-01-25", "completion_date": "2020-11-20", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-18T12:48:51.795Z", "location_count": 17, "location_summary": "San Francisco, California • Santa Monica, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02646748" }, { "nct_id": "NCT06743126", "title": "SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma, Cutaneous Malignant" ], "interventions": [ { "name": "IMA203", "type": "BIOLOGICAL" }, { "name": "nivolumab plus relatlimab", "type": "BIOLOGICAL" }, { "name": "lifileucel", "type": "BIOLOGICAL" }, { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "BIOLOGICAL" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "paclitaxel plus carboplatin", "type": "DRUG" }, { "name": "Albumin-Bound Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Immatics US, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2025-01-14", "completion_date": "2031-10", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-18T12:48:51.795Z", "location_count": 43, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06743126" }, { "nct_id": "NCT00550654", "title": "Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Melanoma (Skin)", "Metastatic Cancer", "Ovarian Cancer", "Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "questionnaire administration", "type": "OTHER" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "hypofractionated radiation therapy", "type": "RADIATION" }, { "name": "image-guided radiation therapy", "type": "RADIATION" }, { "name": "tomotherapy", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "RADIATION" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2007-10", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-10-18T12:48:51.795Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00550654" }, { "nct_id": "NCT00002786", "title": "Biological Therapy in Treating Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "therapeutic tumor infiltrating lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "1995-10", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2010-05-10", "last_synced_at": "2026-10-18T12:48:51.795Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002786" }, { "nct_id": "NCT04521686", "title": "Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cholangiocarcinoma", "Chondrosarcoma", "Glioma", "Any Solid Tumor" ], "interventions": [ { "name": "LY3410738", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2020-10-01", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-18T12:48:51.795Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04521686" }, { "nct_id": "NCT04420273", "title": "Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "SSE educational intervention", "type": "BEHAVIORAL" }, { "name": "Active control:Healthy Living", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1000, "start_date": "2020-07-02", "completion_date": "2021-03-01", "has_results": true, "last_update_posted_date": "2021-11-23", "last_synced_at": "2026-10-18T12:48:51.795Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04420273" }, { "nct_id": "NCT03407170", "title": "Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-06-28", "completion_date": "2019-08-14", "has_results": true, "last_update_posted_date": "2020-07-15", "last_synced_at": "2026-10-18T12:48:51.795Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03407170" }, { "nct_id": "NCT00087386", "title": "Tanespimycin in Treating Patients With Stage III-IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage III Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2004-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-10", "last_synced_at": "2026-10-18T12:48:51.795Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087386" }, { "nct_id": "NCT04895709", "title": "A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Cancer", "Gastric/Gastroesophageal Junction Adenocarcinoma", "Microsatellite Stable Colorectal Cancer", "Non-Small-Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Carcinoma, Renal Cell", "Urothelial Carcinoma", "Pancreatic Adenocarcinoma", "Melanoma", "Ovarian Neoplasms", "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "BMS-986340", "type": "DRUG" }, { "name": "BMS-936558-01", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1109, "start_date": "2021-05-27", "completion_date": "2031-08-31", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-18T12:48:51.795Z", "location_count": 11, "location_summary": "Clovis, California • Los Angeles, California • Newport Beach, California + 6 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895709" }, { "nct_id": "NCT02482532", "title": "Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "tvs-CTL Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gary Doolittle", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 7, "start_date": "2016-10-06", "completion_date": "2021-09-13", "has_results": false, "last_update_posted_date": "2022-02-04", "last_synced_at": "2026-10-18T12:48:51.795Z", "location_count": 1, "location_summary": "Fairway, Kansas", "locations": [ { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02482532" } ] }